Maintenance of immune tolerance depends on normal tissue homeostasis

Journal of Immunology

Volumn 175, Issue 7, 2005, Pages 4247-4254

  Boonman, Zita F H M ^a   Van Mierlo, Geertje J D ^a   Fransen, Marieke F ^a   De Keizer, Rob J W ^a   Jager, Martine J ^a   Melief, Cornelis J M ^a   Toes, René E M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE;

ANATOMY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; ANTIGEN EXPRESSION; ARTICLE; BENIGN TUMOR; CELL ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HOMEOSTASIS; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INOCULATION; INTRAOCULAR TUMOR; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBMANDIBULAR GLAND; T LYMPHOCYTE; TISSUE INJURY; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION; VIRUS INFECTION;

EID: 25444449507     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.7.4247     Document Type: Article

References (48)

1. Mathis, D., and C. Benoist. 2004. Back to central tolerance. Immunity 20: 509-516.
2. + T-helper and a T-killer cell. Nature 393: 474-478.
3. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
4. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393: 478-480.
5. - tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl. Acad. Sci. USA 99: 5561-5566.
6. Polans, A. S., M. D. Burton, T. L. Haley, J. W. Gabb, and K. Palczewski. 1993. Recoverin, but not visinin, is an amoantigen in the human retina identified with a cancer-associated retinopathy. Invest. Ophthalmol. Vis. Sci. 34: 81-90.
7. Streilein, J. W., S. Masli, M. Takeuchi, and T. Kezuka. 2002. The eye's view of antigen presentation. Hum. Immunol. 63: 435-443.
8. Raviola, G. 1977. The structural basis of the blood-ocular barriers. Exp. Eye Res. 25(Suppl): 27-63.
9. Streilein, J. W. 1993. Immune privilege as the result of local tissue barriers and immunosuppressive microenvironments. Curr. Opin. Immunol. 5: 428-432.
10. Lee, H., J. M. Herndon, R. Barreiro, T. S. Griffith, and T. A. Ferguson. 2002. TRAIL: a mechanism of tumor surveillance in an immune privileged site. J. Immunol. 169: 4739-4744.
11. Ferguson, T. A., D. R. Green, and T. S. Griffith. 2002. Cell death and immune privilege. Int. Rev. Immunol. 21: 153-172.
12. Streilein, J. W. 2003. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3: 879-889.
13. Streilein, J. W., J. Y. Niederkorn, and J. A. Shadduck. 1980. Systemic immune unresponsiveness induced in adult mice by anterior chamber presentation of minor histocompatibility antigens. J. Exp. Med. 152: 1121-1125.
14. Egan, R. M., C. Yorkey, R. Black, W. K. Loh, J. L. Stevens, E. Storozynsky, E. M. Lord, J. G. Frelinger, and J. G. Woodward. 2000. In vivo behavior of peptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy. J. Immunol. 164: 4543-4550.
15. + T regulatory cells following antigen inoculation in an immune-privileged site. J. Immunol. 171: 1266-1271.
16. + T cells. J. Immunol. 169: 5630-5637.
17. Kosiewicz, M. M., S. Okamoto, S. Mild, B. R. Ksander, T. Shimizu, and J. W. Streilein. 1994. Imposing deviant immunity on the presensitized state. J. Immunol. 153: 2962-2973.
18. Mullaney, P. B., Z. A. Karcioglu, S. al-Mesfer, and E. B. Abboud. 1997. Presentation of retinoblastoma as phthisis bulbi. Eye 11(Pt. 3): 403-408.
19. Tripathi, A., P. Hiscott, and B. E. Damato. 2002. Malignant melanoma and massive retinal gliosis in phthisis bulbi. Eye 16: 781-782.
20. Boonman, Z. F., G. J. van Mierlo, M. F. Fransen, K. L. Franken, R. Offringa, C. J. Melief, M. J. Jager, and R. E. Toes. 2004. Intraocular tumor antigen drains specifically to submandibular lymph nodes, resulting in an abortive cytotoxic T cell reaction. J. Immunol. 172: 1567-1574.
21. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93: 7855-7860.
22. Medema, J. P., J. de Jong, T. van Hall, C. J. Melief, and R. Offringa. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190: 1033-1038.
23. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5: 774-779.
24. Schurmans, L. R., A. T. den Boer, L. Diehl, E. I. van der Voort, W. M. Kast, C. J. Melief, R. E. Toes, and M. J. Jager. 1999. Successful immunotherapy of an intraocular tumor in mice. Cancer Res. 59: 5250-5254.
25. + T cells. Cell 71: 1205-1214.
26. Schoenberger, S. P., E. I. van der Voort, G. M. Krietemeijer, R. Offringa, C. J. Melief, and R. E. Toes. 1998. Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells. J. Immunol. 161: 3808-3812.
27. + T cells by exogenous cell-associated antigens. Immunity 17: 211-220.
28. Pierre, P., S. J. Turley, E. Gatti, M. Hull, J. Meltzer, A. Mirza, K. Inaba, R. M. Steinman, and I. Mellman. 1997. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388: 787-792.
29. Toes, R. E., R. J. Blom, E. van der Voort, R. Offringa, C. J. Melief, and W. M. Kast. 1996. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res. 56: 3782-3787.
30. Toes, R. E., E. I. van der Voort, S. P. Schoenberger, J. W. Drijfhout, L. van Bloois, G. Storm, W. M. Kast, R. Offringa, and C. J. Melief. 1998. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J. Immunol. 160: 4449-4456.
31. + B cells cultured from the vitreous in acute sympathetic ophthalmitis. Autoimmunity 15: 257-266.
32. + CTL to cause tumor eradication. J. Immunol. 173: 6753-6759.
33. Sigal, L. J., S. Crotty, R. Andino, and K. L. Rock. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398: 77-80.
34. + T cell tolerance. Immunity 18: 713-720.
35. Inaba, K., S. Turley, T. Iyoda, F. Yamaide, S. Shimoyama, C. Reis e Sousa, R. N. Germain, I. Mellman, and R. M. Steinman. 2000. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J. Exp. Med. 191: 927-936.
36. + T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity. J. Exp. Med. 186: 2057-2062.
37. + T lymphocytes into effector CTL. J. Immunol. 172: 6558-6567.
38. Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5: 1249-1255.
39. Singh-Jasuja, H., H. U. Scherer, N. Hilf, D. Arnold-Schild, H.-G. Rammensee, R. E. Toes, and H. Schild. 2000. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol. 30: 2211-2215.
40. Scaffidi, P., T. Misteli, and M. E. Bianchi. 2002. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191-195.
41. Shi, Y., J. E. Evans, and K. L. Rock. 2003. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425: 516-521.
42. Darnell, R. B., and J. B. Posner. 2003. Paraneoplastic syndromes involving the nervous system. N. Engl. J. Med. 349: 1543-1554.
43. Musunuru, K., and R. B. Darnell. 2001. Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. Annu. Rev. Neurosci. 24: 239-262.
44. Ogg, G. S., P. Rod Dunbar, P. Romero, J. L. Chen, and V. Cerundolo. 1998. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med 188: 1203-1208.
45. + T cells in melanoma-associated vitiligo. J. Invest. Dermatol. 117; 1464-1470.
46. Rosenberg, S. A., and D. E. White. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19: 81-84.
47. Yee, C., J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg. 2000. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. 192: 1637-1644.
48. Damell, R. B., and J. B. Posner. 2003. Observing the invisible: successful tumor immunity in humans. Nat. Immunol. 4: 201.